glp 1 for liver Mechanism of action GLP-1R agonists. Primarily expressed in the GLP-1_receptor_som_behandling_af_steatotisk_leversygdom - SDU
Description
Tirzepatide also showed improvements in lipids and cardiovascular risk factors compared to dulaglutide 1.5 mg and placebo
The group is not for dosing advice or medication sourcing
In those situations, lowering the dose may temporarily reduce symptoms, but it does not address the underlying sleep disruption that is contributing to the problem
Serious risks are rare but possible in immunocompromised individuals or those with severe underlying health conditions
